GenoLogics announced that it has signed a three year global agreement with Pfizer to provide informatics solutions to its research labs.
Under the terms of the agreement, GenoLogics will provide an enterprise enabled lab and data management system to capture, contextualize and integrate science data in multiple locations world wide.
In addition to the ability to leverage data standards across labs by virtue of a common informatics platform, GenoLogics will provide Pfizer with the tools to enable web-based collaboration, bioinformatics pipelining, auditability and reporting of cross-science data.
“We are excited to be working with Pfizer on a global basis and supporting their research centers with informatics solutions that we can customize by lab regardless of their science,” exclaims Michael Ball, CEO of GenoLogics. “Expanding our client base to include the world’s largest pharmaceutical company is a significant milestone for GenoLogics and one that reinforces how our collaborative approach with clients ensures we deploy solutions that enable our client’s success.”
GenoLogics provides research organizations with informatics solutions from the discovery to biomedical areas, including integrated products for managing biorepositories and clinical annotations to lab and data management systems for genomics, proteomics and other sciences.
The GenoLogics suite of products is developed on a common informatics platform, providing clients with a holistic solution that connects data contextually and improves the efficiency of their lab operations.
“We required a vendor that provides a highly flexible and configurable solution that can be customized for a wide range of workflows and ever-changing technologies that are employed at our research centers,” indicated Giles Day, Head, BBC Informatics at Pfizer. “The GenoLogics informatics solution can be customized at the lab level, including instrument integrations and data imports, while allowing us to analyze data across sciences and labs.”